OCUP vs. HCWB, NXTC, GANX, EYEN, CASI, VYNE, NBRV, UNCY, AADI, and XLO
Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include HCW Biologics (HCWB), NextCure (NXTC), Gain Therapeutics (GANX), Eyenovia (EYEN), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Nabriva Therapeutics (NBRV), Unicycive Therapeutics (UNCY), Aadi Bioscience (AADI), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Ocuphire Pharma (NASDAQ:OCUP) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by company insiders. Comparatively, 45.3% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ocuphire Pharma has a net margin of -59.44% compared to HCW Biologics' net margin of -697.53%. Ocuphire Pharma's return on equity of -24.57% beat HCW Biologics' return on equity.
Ocuphire Pharma has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Ocuphire Pharma received 28 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 68.00% of users gave Ocuphire Pharma an outperform vote.
Ocuphire Pharma currently has a consensus target price of $18.75, suggesting a potential upside of 1,012.76%. Given Ocuphire Pharma's higher possible upside, equities analysts plainly believe Ocuphire Pharma is more favorable than HCW Biologics.
Ocuphire Pharma has higher revenue and earnings than HCW Biologics. Ocuphire Pharma is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ocuphire Pharma had 10 more articles in the media than HCW Biologics. MarketBeat recorded 16 mentions for Ocuphire Pharma and 6 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.09 beat Ocuphire Pharma's score of -0.46 indicating that HCW Biologics is being referred to more favorably in the news media.
Summary
Ocuphire Pharma beats HCW Biologics on 12 of the 18 factors compared between the two stocks.
Get Ocuphire Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocuphire Pharma Competitors List
Related Companies and Tools
